Cancer therapy shows promise for psoriasis treatment
June 22, 2017
CDC: Hepatitis C cases reach 15-year high
June 22, 2017
Show all

AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial

AbbVie’s rheumatoid arthritis drug is performing well in trials.

U.S. drugmaker AbbVie said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments.

Two doses of the drug, upadacitinib, induced a statistically significant reduction in symptoms compared to a placebo in the 12-week long study, AbbVie said.

Nearly half of the patients achieved low disease activity at both doses and around 30 percent achieved clinical remission, data showed.

Rheumatoid arthritis is a chronic inflammatory autoimmune disease in which the immune system attacks the tissues of the joints, causing inflammation, pain, joint damage and disability.

Upadacitinib is a once-daily pill belonging to a class of drugs known as Jak inhibitors, which block inflammation-causing enzymes known as Janus kinases.

Read full article: AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial

Read Full Article: AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.